Chris Shibutani

can you comment about the potential impact of some of these combination approaches in immunology? Do you expect these to be IP extending

There have been several advancements of time lines in terms of data readouts. And there's also been an absence of slippage

What is embedded in that assumption? Can you talk a little bit about the approach for timing of Orforglipron in terms of diabetes versus obesity?

On the pipeline, I noticed in Phase 2, you've advanced the GIP antagonist. Is that something that you'll be continuing to share data on

Are you solving for near-term revenues, or are you looking to use other methods, including perhaps partnerships over M&A?